This video has been sponsored by LivaNova.
The RESPOND-CRT clinical trial is a relevant and significant study in the field of cardiac resynchronisation therapy. It has answered an important question finally, that optimisation can work, and that optimisation, if done on an individual basis, in an automatic fashion, repetitively, can actually translate into better outcomes. Not only was there a significant reduction in heart failure hospitalisation for patients in the SonR arm, there were also significant benefits found for sicker patients, in particular those with a history of atrial fibrillation and renal failure. Jagmeet Singh (Boston, USA), Angelo Aurrichio (Lugano, Switzerland) and Josep Brugada (Barcelona, Spain) discuss the results of the subanalysis conducted on patient subgroups and the implications for clinical practice. To learn more please click here